MassDevice Q&A: Jean-Marc Wismer
July 14, 2009 by Brian Johnson
The CEO of Switzerland's Sensimed looks to peel back the lid on glaucoma testing.
You literally cannot see glaucoma coming.
Although it's one of the leading causes of blindness in the world, frighteningly little is known about a disease group that affects 4 percent of the world's population over the age of 40. No cure is on the horizon. And due to the insidious nature of the disease, which stars gradually affecting sight from the periphery, most people don't even know they're suffering from glaucoma until it's too late.
Swiss diagnostics company Sensimed AG sees this mysterious disease as a real opportunity.
Similar entries
Permalink
FDA Database Search
RECENT BLOG POSTS
- Funding R&D: High prices, overuse a failed strategy
- FDA's role in promoting women's health
- New partnership to boost use of GMDN codes for medical devices
- FDA's modern "Corps of Discovery" in China
- Consumers lose in latest FDA user fee bill; COI restraints disappear
- Gamification
- Cool technology of the week
- A new day: Interim thoughts on the 2012 Heart Rhythm Society scientific sessions
- When a child loses milestones, consider sleep EEG studies
- Red or blue pill for payment reform? Both won't work
Features
